170 related articles for article (PubMed ID: 19738461)
41. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Li Y; Feng M; Guo T; Wang Z; Zhao Y
Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
[TBL] [Abstract][Full Text] [Related]
42. β-lapachone regulates mammalian inositol pyrophosphate levels in an NQO1- and oxygen-dependent manner.
Eisenbeis VB; Qiu D; Gorka O; Strotmann L; Liu G; Prucker I; Su XB; Wilson MSC; Ritter K; Loenarz C; Groß O; Saiardi A; Jessen HJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2306868120. PubMed ID: 37579180
[TBL] [Abstract][Full Text] [Related]
43. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
44. NQO1 induction mediated by photodynamic therapy synergizes with β-Lapachone-halogenated derivative against melanoma.
Lamberti MJ; Morales Vasconsuelo AB; Chiaramello M; Ferreira VF; Macedo Oliveira M; Baptista Ferreira S; Rivarola VA; Rumie Vittar NB
Biomed Pharmacother; 2018 Dec; 108():1553-1564. PubMed ID: 30372857
[TBL] [Abstract][Full Text] [Related]
45. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW
Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184
[TBL] [Abstract][Full Text] [Related]
46. β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
Qadir MI; Iqbal MS; Khan R
Curr Cancer Drug Targets; 2022; 22(7):537-540. PubMed ID: 35490325
[TBL] [Abstract][Full Text] [Related]
47. eIF2 kinases mediate β-lapachone toxicity in yeast and human cancer cells.
Menacho-Márquez M; Rodríguez-Hernández CJ; Villaronga MÁ; Pérez-Valle J; Gadea J; Belandia B; Murguía JR
Cell Cycle; 2015; 14(4):630-40. PubMed ID: 25590579
[TBL] [Abstract][Full Text] [Related]
48. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
49. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
50. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
51. β-Lapachone, an NQO1 activator, alleviates diabetic cardiomyopathy by regulating antioxidant ability and mitochondrial function.
Wu PY; Lai SY; Su YT; Yang KC; Chau YP; Don MJ; Lu KH; Shy HT; Lai SM; Kung HN
Phytomedicine; 2022 Sep; 104():154255. PubMed ID: 35738116
[TBL] [Abstract][Full Text] [Related]
52. The metabolism of 9-chloro-β-lapachone and its effects in isolated hepatocytes. The involvement of NAD(P)H:quinone oxidoreductase 1 (NQO1).
Fernandez Villamil SH; Carrizo PH; Di Rosso ME; Molina Portela MP; Dubin M
Chem Biol Interact; 2012 Dec; 200(2-3):84-91. PubMed ID: 23047025
[TBL] [Abstract][Full Text] [Related]
53. Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer.
Chang MC; Mahar R; McLeod MA; Giacalone AG; Huang X; Boothman DA; Merritt ME
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893874
[TBL] [Abstract][Full Text] [Related]
54. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
[TBL] [Abstract][Full Text] [Related]
55. Mu-calpain activation in beta-lapachone-mediated apoptosis.
Tagliarino C; Pink JJ; Reinicke KE; Simmers SM; Wuerzberger-Davis SM; Boothman DA
Cancer Biol Ther; 2003; 2(2):141-52. PubMed ID: 12750552
[TBL] [Abstract][Full Text] [Related]
56. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
57. β-Lapachone, an NQO1 bioactivatable drug, prevents lung tumorigenesis in mice.
Chen Y; Wu R; Li X; Cao M; Yang M; Fu B; Xuan C; Chen C; Zhou Y; Hu R
Eur J Pharmacol; 2024 Jun; 973():176511. PubMed ID: 38604545
[TBL] [Abstract][Full Text] [Related]
58. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
59. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.
Miyamoto S; Huang TT; Wuerzberger-Davis S; Bornmann WG; Pink JJ; Tagliarino C; Kinsella TJ; Boothman DA
Ann N Y Acad Sci; 2000; 922():274-92. PubMed ID: 11193903
[TBL] [Abstract][Full Text] [Related]
60. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
